Neuralink is set to begin human trials of its Blindsight brain implant in the United Arab Emirates in early 2026, partnering with Cleveland Clinic Abu Dhabi. The device aims to restore vision by bypassing damaged eyes entirely and transmitting visual signals directly to the brain's visual cortex.
Unlike traditional vision restoration approaches, Blindsight can work even for people born completely blind or those with no functioning optic nerve. Elon Musk stated during a previous Neuralink presentation: "The visual part of the cortex is still there. Even if they've never seen before, we're confident they could see."
The FDA has granted Blindsight "breakthrough device" designation, expediting its path toward approval. Neuralink has already implanted its Link brain-computer interface in twelve patients with severe paralysis, demonstrating the technology's ability to control digital devices through thought alone.
Musk announced that 2026 will see Neuralink transition to "high-volume production" of its devices and implement "almost entirely automated" surgical procedures. The company secured $650 million in funding last June to support this expansion. However, experts remain skeptical—IEEE Spectrum notes that the implant likely won't deliver "natural sight" and that the brain operates on far more complex systems than engineers typically assume.
